Literature DB >> 10204752

Enadoline, a selective kappa-opioid receptor agonist shows potent antihyperalgesic and antiallodynic actions in a rat model of surgical pain.

M J Field1, A J Carnell, M I Gonzalez, S McCleary, R J Oles, R Smith, J Hughes, L Singh.   

Abstract

Enadoline is a highly selective and potent kappa-opioid receptor agonist. This report describes and compares the activities of enadoline and morphine in a rat model of postoperative pain. A 1 cm incision through the muscle and skin of the plantar surface of the right hind paw induced thermal hyperalgesia as well as static and dynamic allodynia lasting at least 2 days. Postoperative testing was carried out using the plantar test for thermal hyperalgesia, von Frey hairs for static allodynia and light stroking with a cotton bud for dynamic allodynia. A single i.v. dose of enadoline 15 min before surgery dose-dependently (1-100 microg/kg) blocked the development of thermal hyperalgesia as well as static and dynamic allodynia for over 24 h with respective MEDs of < or = 1, 10 and 10 microg/kg. The administration of enadoline (100 microg/kg, i.v.), 1 h after surgery, completely blocked the maintenance of the hyperalgesic and allodynic responses, but its duration of action was much shorter (2 h) than when administered before surgery. Previous studies have shown that administration of morphine (1-6 mg/kg, s.c.) 0.5 h before surgery can prevent the development of thermal hyperalgesia with a MED of < or =1 mg/kg, but it has little effect on static allodynia. In the present study similar administration of morphine (1-3 mg/kg), unlike enadoline, had no effect on the development of dynamic allodynia. Morphine dose-dependently (1-6 mg/kg, s.c.) potentiated isoflurane-induced sleeping time and respiratory depression in the rat. However, whilst enadoline also (1-1000 microg/kg, i.v.) potentiated isoflurane-induced sleeping time, it did not cause respiratory depression. It is suggested that enadoline may possess therapeutic potential as a pre-emptive antihyperalgesic and antiallodynic agent.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10204752     DOI: 10.1016/s0304-3959(98)00237-1

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  9 in total

Review 1.  Kappa opioids and the modulation of pain.

Authors:  Bronwyn Kivell; Thomas E Prisinzano
Journal:  Psychopharmacology (Berl)       Date:  2010-04-07       Impact factor: 4.530

2.  Dissociable effects of the kappa opioid receptor agonist nalfurafine on pain/itch-stimulated and pain/itch-depressed behaviors in male rats.

Authors:  Matthew L Lazenka; Megan J Moerke; E Andrew Townsend; Kevin B Freeman; F Ivy Carroll; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2017-10-24       Impact factor: 4.530

Review 3.  The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies.

Authors:  Martin L Dalefield; Brittany Scouller; Rabia Bibi; Bronwyn M Kivell
Journal:  Front Pharmacol       Date:  2022-06-20       Impact factor: 5.988

4.  Pharmacological characterisation of a rat model of incisional pain.

Authors:  Garth T Whiteside; James Harrison; Jamie Boulet; Lilly Mark; Michelle Pearson; Susan Gottshall; Katharine Walker
Journal:  Br J Pharmacol       Date:  2003-11-03       Impact factor: 8.739

5.  Effects of combined opioids on pain and mood in mammals.

Authors:  Richard H Rech; David J Mokler; Shannon L Briggs
Journal:  Pain Res Treat       Date:  2012-03-21

Review 6.  Potential for Kappa-Opioid Receptor Agonists to Engineer Nonaddictive Analgesics: A Narrative Review.

Authors:  Shane W Kaski; Allison N White; Joshua D Gross; David P Siderovski
Journal:  Anesth Analg       Date:  2021-02-01       Impact factor: 6.627

7.  Agitation in the ICU: part one Anatomical and physiologic basis for the agitated state.

Authors: 
Journal:  Crit Care       Date:  1999       Impact factor: 9.097

Review 8.  The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential.

Authors:  Gerald W Zamponi; Joerg Striessnig; Alexandra Koschak; Annette C Dolphin
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 9.  Opioid Receptor Regulation of Neuronal Voltage-Gated Calcium Channels.

Authors:  Norbert Weiss; Gerald W Zamponi
Journal:  Cell Mol Neurobiol       Date:  2020-06-08       Impact factor: 5.046

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.